Global Cancer Technology
OperatingGlobal Cancer Technology, Inc.
Healthcare · Founded 2017
GCT’s lead cancer technology is its remote-controlled cancer drug delivery platform.
Financials
FY2017–FY2020 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inBlue bars are the pre-money valuation the company stated for a priced round. Dotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.
Cap table
Share counts as of Dec 31, 2020| Class | Outstanding | Votes / share | Share of total | Last price |
|---|---|---|---|---|
| Common Stock | 13,053,838 | 1 | 100.0% | $1.00Oct 2019 |
Sold to the crowd
- Reg CF · Oct 2019107,000 shares at $1.00$107K
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
4 peopleNames and titles as disclosed on SEC Form 1-A, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 1 of 7 annual reports (FY2019–FY2025)
Missing: 2019, 2021, 2022, 2023, 2024, 2025
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 24 filings on EDGAR- Form C/AApr 6, 20220001669191-22-000362EDGAR
- Form CFeb 7, 20220001669191-22-000106EDGAR
- Form C-ARJan 27, 20220001669191-22-000066EDGAR
- Form 1-SADec 29, 20210001683168-21-006627EDGAR
- Form 1-KJul 13, 20210001683168-21-002923EDGAR
- Form QUALIFNov 25, 20209999999994-20-000269EDGAR
- Form 1-A/ANov 24, 20200001683168-20-004081EDGAR
- Form 1-A/AOct 30, 20200001683168-20-003612EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.